Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based Partner operating in the Venture Capital space. If you think a Partner is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Parul Singh
Partner of Initialized Capital
Parul Singh is a product-driven founder and investor with a background in engineering, product strategy, and analytics. Parul spent the past five years on the investing team at Founder Collective, a tech-focused, early-stage seed fund where she covered Boston and NYC, evaluated over 3,000 companies, and spearheaded the firm’s investments in Embark Veterinary, Broadlume, Running Tide, HumanFirst, Flume Health, and HealthNote. Prior to investing, she spent close to a decade as an engineer and product manager at the NYTimes.com, Inc. and Fast Company, and she was the founder of a learning analytics company. At Initialized, Parul will focus her investing efforts on software companies, with a special interest in the areas of healthtech, SaaS, and analytics. Parul has an undergraduate degree from Harvard College and an MBA from MIT.
Follow Parul Singh:
About Initialized Capital: Initialized Capital is an early-stage VC firm focused on helping software engineers and designers with their first seed checks.
Chris Price
Partner of Oak HC/FT
Partner @ Oak HC/FT | Co-Founder @ WithMe Health | Investor & Entrepreneur I am a product focused investor and business builder that is passionate about making our healthcare system better. As such, I seek to invest in teams that are focused on driving meaningful improvements in quality, cost and patient experience. During my 15+ year investing and operating career, I’ve tried a lot of different things resulting in some great successes and humbling failures. My investing experience has spanned all stages and every level of the capital structure. As an operator, I have helped build businesses ranging from early-stage start-ups to private equity backed assets with multi-billions in revenue. All of this has resulted in exits representing over $4.5 billion in aggregate value. Within healthcare, I am currently interested in pharma services for complex therapies, risk bearing care management and delivery models within specific specialties, network optimization solutions, clinical and operational workflow optimization, opportunities to disrupt the pharmaceutical value chain and solutions that enable employers to obtain significantly better results for their healthcare dollars. I put people first, constantly challenge convention, enjoy learning, think design is important and always look forward to the future.
Follow Chris Price:
About Oak HC/FT: Oak HC/FT is a venture and growth equity investment firm that focuses on healthcare information services and financial service technology.
Nancy G. Brown
General Partner of Oak HC/FT
Nancy G. Brown, Vice President of Strategy and Business Development for McKesson Technology Solutions, has more than 25 years of experience in clinical research and automating clinical information systems, combining management, consulting and information technology skills. At McKesson, she is responsible for helping the company develop, acquire and apply new capabilities that position it to lead the industry and accelerate its Better Health 2020™ strategy, helping healthcare networks reduce costs, coordinate care, assume more risk and manage complex payment models.
Follow Nancy G. Brown:
About Boston Children’s Hospital, Oak HC/FT, Oak HC/FT: Oak HC/FT is a venture and growth equity investment firm that focuses on healthcare information services and financial service technology.
Nancy Brown
General Partner of Oak HC/FT
Nancy Brown (HC), a General Partner at Oak HC/FT, joined the firm in 2014 and focuses on growth equity and early-stage venture opportunities in Healthcare. Nancy currently serves on the Board of Axial Healthcare, Cricket Health, Maven, and Unite US. She is also a Board Observer at Limeade. Prior to joining Oak HC/FT, Nancy was Vice President of Strategy and Business Development for McKesson Technology Solutions. Previously, Nancy was Chief Growth Officer at MedVentive, which was acquired by McKesson in 2012. Before joining MedVentive, she served as Senior Vice President of Corporate Development as well as Senior Vice President of Clinical Service of athenahealth. Prior to joining athenahealth in 2004, she was a Senior Vice President at McKesson Corporation, focused on marketing and strategic planning. She joined McKesson in 1999 when it acquired a company she co-founded, Abaton.com, a provider of internet-based clinical solutions for the ambulatory market. Earlier, she spent eight years at Harvard Community Health Plan where she held several senior management roles. Nancy is also on the New England Capital Association Board of Directors and is a mentor for MassChallenge. Nancy received a Bachelor of Science at the University of New Hampshire and an MBA from Northeastern University.
Follow Nancy Brown:
About Oak HC/FT: Oak HC/FT is a venture and growth equity investment firm that focuses on healthcare information services and financial service technology.
Onsi Sawiris
Co-Founder and Managing Partner of HOF Capital
Onsi Sawiris is a Co-Founder and Managing Partner at HOF Capital, where he focuses on cloud-based technologies, fintech and enterprise SaaS. Onsi currently sits on the boards of Drop Technologies (Canada), ItaliaOnline (BIT:IOL) (Italy), Riverbank (EU), OPTii Solutions (US), Mach Music (US), Energal (Egypt), and is a Board Observer at Orascom TMT Investments (Luxembourg, Egypt, UK). His focus is on supporting these companies with digital transformation strategies, and finding synergies with HOF’s portfolio. Prior to HOF Capital, Onsi worked in TMT-focused M&A at Arma Partners, a specialist technology investment bank. Onsi also co-founded Energal, a hyperlocal sustainable energy company tackling distribution inefficiencies in emerging markets. Onsi holds a BSc in Mechanical Engineering from the Massachusetts Institute of Technology (MIT). He is fluent in English, German and Arabic with a working proficiency in French.
Follow Onsi Sawiris:
About HOF Capital: HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.
Arsham Memarzadeh
Partner of Lightspeed Venture Partners
Born the son of an Iranian immigrant and entrepreneur, Arsham developed an early appreciation for the resilience and ingenuity required to win, even when all the cards are stacked against you. “Building a company requires countless instances of running through, breaking down, and climbing over walls,” said Arsham. “Entrepreneurs are a rare breed and in a league of their own. Working alongside them, enabling their success, is what makes my day-to-day rewarding.” Arsham joined Lightspeed’s growth practice in 2019 to invest in product-driven software companies. He has a passion for evolving distribution models and believes the best companies find GTM leverage out of the product itself. “Consumerization of the enterprise has just as much to do with evolving sales motions as it does with building better products,” said Arsham. “Historically, company-building has been bifurcated into product development and product distribution. The next generation of great software companies will combine those worlds.” Before moving West, Arsham spent five years in Boston at the expansion stage venture firm, OpenView, where he invested in companies like Deputy, Highspot, and GitPrime, among others. He’s backed companies across three continents, in unlikely geographies and led by unassuming entrepreneurs, so it’s no surprise that Lightspeed’s global platform was part of what drew him to the firm. “I love finding great companies that might not follow popular narratives or be the golden child of Silicon Valley,” said Arsham. “I wholeheartedly believe innovation extends beyond the confines of the Bay Area.” Prior to investing, Arsham was a growth consultant, advising SaaS companies and helping analyze market and customer data to define product and GTM strategies. Arsham studied Industrial and Labor Relations at Cornell University and is an active member of the school’s Entrepreneurship Advisory Council. When he’s not working, you can usually find him exploring all things outdoors or doing his best to not burn down the kitchen while cooking.
Follow Arsham Memarzadeh:
About Lightspeed Venture Partners: Lightspeed Venture Partners is a venture capital firm that engages in consumer, enterprise, technology, and cleantech markets.
David García
CEO | Founding Managing Partner of Borderless Capital
Former Entrepreneur, Investor and current Founder & Managing Partner at Algo Capital.
Follow David García:
About Algorand, Borderless Capital, Crypto Assets Fund, Ripio: Borderless Capital is a Blockchain-focused venture capital group.
Rob May
Venture Partner of PJC
Rob May is a General Partner at PJC with expertise in the areas of AI, hardware, B2B, and SaaS. Prior to joining PJC, Rob was the co-founder and CEO at Talla, an AI and automation platform, transforming the way businesses deliver customer support. He was also the co-founder and CEO of Backupify, the world’s first cloud to cloud backup provider which was acquired for over $100m. As an angel investor, he made over 70 early-stage AI investments. Rob writes the world’s most popular newsletter on Artificial Intelligence – InsideAI.
Follow Rob May:
About BotChain, Half Court VC, PJC, Talla: PJC is an early-stage venture capital firm with a focus on enterprise, consumer, and artificial intelligence.
David Martirano
Co-Founder & Managing Partner of PJC
David Martirano is the Managing Partner of PJC. David has extensive experience investing broadly in B2B SaaS, Consumer and Tech Enabled Service companies. In 2001, David partnered with Governor Gina Raimondo, and together they founded Point Judith Capital in Rhode Island. Point Judith Capital subsequently relocated to Boston in 2011 and later rebranded to PJC. Prior to PJC, David Co-founded Rex Capital Ventures, which was a venture division of a family office that invested in early stage technology companies around the world. Before embarking on his 20-year venture capital experience, he worked on Wall street and was a member of the Investment Banking Group at Cowen & Company. David sits on the Board of Trustees at the University of Rhode Island and the Investment Committee of Lifespan and has been actively involved with Year Up Rhode Island.
Follow David Martirano:
About PJC: PJC is an early-stage venture capital firm with a focus on enterprise, consumer, and artificial intelligence.
Matthew Hayes
General Partner of PJC
Follow Matthew Hayes:
About PJC: PJC is an early-stage venture capital firm with a focus on enterprise, consumer, and artificial intelligence.
Shawn Broderick
General Partner of SOSV
Shawn Broderick has more than twenty years of experience creating value in software companies as individual contributor, entrepreneur, intrapraneur, manager, investor, and leader. Shawn has extensive experience in business development, sales, and partnering, with repeated success in developing products from concept to customer. Shawn brings an exceptional track record of sourcing, hiring, and retaining stellar employees to SOSV. He prides himself on identifying both diamonds-in-the-rough as well as young talent – and grooming and extracting the best from both. Being adept at managing business teams, technical teams, and creative teams, it’s no surprise that Shawn has broad experience raising institutional and angel funds for businesses and in sourcing LPs for investment vehicles.
Follow Shawn Broderick:
About AYLIEN, dlab, Food-X, SOSV: SOSV is a global VC firm with $1B AUM and 1,000+ investments, that operates HAX, IndieBio, Chinaccelerator, MOX, and dlab.
Reuben Kobulnik
Operating Partner of Valar Ventures
Operating Partner at Valar Ventures.
Follow Reuben Kobulnik:
About Valar Ventures: Valar Ventures is a venture capital firm that invests in technology companies.
Jason Pontin
Partner of DCVC
Jason Pontin FRSA is the editor in chief and publisher of M.I.T.’s Technology Review. He was hired as the editor of Technology Review in July 2004, and in August 2005 was named publisher. From 1996 to 2002, Pontin was the editor of Red Herring, a business and technology publication that was popular during the dot-com boom. From 2002 to 2004, he was the editor of The Acumen Journal, a now-defunct magazine about the life sciences that he founded. Pontin has written for a number of national and international magazines and newspapers, including The New York Times, The Economist, The Financial Times, The Believer Magazine, and Wired. He is also a frequent guest on broadcast, public, and cable television news. Finally, he is a Fellow of the Royal Society of Arts (FRSA).
Follow Jason Pontin:
About DCVC, MIT’s Technology Review Magazine: DCVC backs entrepreneurs using Deep Tech to solve problems and multiply the benefits of capitalism for everyone while reducing its cost.
Krishna Yeshwant
Managing Partner of GV
Dr. Krishna Yeshwant is a physician, programmer, and entrepreneur who has been working with GV since its inception. He first joined Google as part of the New Business Development team. Prior to Google he helped start an electronic data interchange company that was acquired by Hewlett-Packard and a network security company that was acquired by Symantec. He also co-authored the business plan for Diagnostics For All, which won both the Harvard Business School and MIT $100k business plan competitions. Previously, Krishna published several book chapters and journal articles in the field of computer-guided surgery, completed research in tissue engineering, and developed and licensed multiple surgical devices. He has worked with the technology transfer offices of MIT, Harvard, and Massachusetts General Hospital. Krishna has a B.S. in computer science from Stanford University. He also earned an M.D. from Harvard Medical School, an MBA from Harvard Business School, and completed his residency at Brigham and Women’s Hospital in Boston, MA where he continues to practice.
Follow Krishna Yeshwant:
About GV, Partners HealthCare, Wingu: GV provides venture capital funding to bold new companies.
David Schenkein
General Partner of GV
Dr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and a member of our Board of Directors and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center and is a member of the board of directors for the Biotechnology Industry Organization, the world’s largest biotechnology trade association, a position he has held since 2012. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. He currently serves on the board of directors of Foundation Medicine, Inc., bluebird bio, Inc., and Blueprint Medicines Inc. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.
Follow David Schenkein:
About GV, Tufts Medical Center: GV provides venture capital funding to bold new companies.
Christina Kelleher
Administrative Business Partner of GV
Christina joined GV in September 2011. Prior to joining the team, she was office manager and executive assistant to the founder/chief creative officer at TOTH+Co, a boutique advertising agency in Cambridge, Massachusetts. Previously, she worked as an event planner at a catering company in Charlestown, Massachusetts, organizing both corporate and social events. She also has experience in the field of public relations, most notably working at Context Marketing in Sausalito, California for the California Milk Advisory Board “Real California Cheese” and “Happy Cows” campaigns. Christina graduated from Syracuse University with a Bachelor of Science in advertising and a Bachelor of Arts in psychology.
Follow Christina Kelleher:
About GV: GV provides venture capital funding to bold new companies.
Jeremiah Daly
Co-Founder and Managing Partner of Elephant
Jeremiah is Co-Founder and Partner at Elephant, a venture capital firm focused on the enterprise software, consumer internet and mobile markets. Previously, he was a Principal at Highland Capital Partners, where he focused on investments in growth stage internet, software, payments and mobile businesses. Prior to joining Highland, Jeremiah was a Principal at Accel Partners in London. While at Accel Jeremiah led the investment in Ostrovok.ru (Russian-focused online travel agency) and was involved with investments in Atlassian (software for streamlining product development), Showroomprive (online private sales club), SimpliVity (IT infrastructure technology for the virtualized data center and cloud) and Supercell (mobile and social games). Earlier, Jeremiah was an investor at Summit Partners and Gold Hill Capital and a banker at Silicon Valley Bank. Jeremiah lives in Boston and has a strong interest in amateur sports. He was the captain of the Dartmouth golf team where he was a two-time Academic All-Ivy performer and also enjoys skiing, squash, tennis, soccer and supporting Boston sports teams.
Follow Jeremiah Daly:
About Elephant, KnowBe4, Malwarebytes: Elephant is a venture capital firm focused on the enterprise software, consumer internet, and mobile markets.
Christopher De Souza
Partner of Elephant
Chris is currently an Investor at Elephant, where he is responsible for sourcing and executing new investments in software and technology. He joined Elephant in 2016 after more than two years as an Associate at Bain Capital. Prior to joining Bain, he was an Analyst at Volition Capital. Chris earned a Bachelor of Arts degree in Economics from Dartmouth College.
Follow Christopher De Souza:
About Elephant: Elephant is a venture capital firm focused on the enterprise software, consumer internet, and mobile markets.
Gus Coldebella
Partner of True Ventures
Gus Coldebella is the Partner at True Ventures.
Follow Gus Coldebella:
About True Ventures: True Ventures is a venture capital firm that invests in early-stage technology startups.
Gus Coldebella
Partner of True Ventures
Gus Coldebella is the Partner at True Ventures.
Follow Gus Coldebella:
About True Ventures: True Ventures is a venture capital firm that invests in early-stage technology startups.
Yumin Choi
Partner of Bain Capital Ventures
Yumin Choi is a Vice President of HLM Venture Partners. Yumin is currently a Director of Vets First Choice and is a board observer at Institute for Health Metrics (IHM), Nordic Consulting, and TYRX. He is a director to The Capital Network, a non-profit focused on educating entrepreneurs around topics of fundraising and finance, He previously was chair of the New England Venture Network (NEVN), the largest young Venture Capital organization in New England. Yumin is co-chair of the Boston Symphony Orchestra Venture Capital and Private Equity committee and is on Boston University’s Coulter Foundation Oversight Committee. Prior to HLM, Yumin was with Angel Healthcare Investors, a health care focused early stage investment group, ZweigWhite’s Financial Advisory Services and Mergers & Acquisitions Group and was co-founder and CEO of CY Digital. He is also a mentor in health care focused startup accelerators, Blueprint Health and Healthbox, and is an active angel investor. Yumin received a BS from Babson College.
Follow Yumin Choi:
About Angel Healthcare Investors, Bain Capital Ventures: Bain Capital Ventures invests in seed to growth-stage startups that uses tech to disrupt existing markets or create entirely new ones.
Michael Krupka
Partner of Bain Capital Ventures
Michael Krupka is a Managing Director at Bain Capital Ventures. Prior to Bain Capital Ventures, Michael Krupka was a Managing Director with the Private Equity Group of Bain Capital, during which time he focused his investing activities on technology and technology-driven companies, including software, hardware, database, and telecommunication services. Earlier at Bain Capital, Michael Krupka was a Principal of Information Partners, a fund focused on early-stage information technology investing. He has also served in several operating roles as President of a $110 M revenue software company and CFO of a $70 M revenue services company. Prior to joining Bain Capital in 1991, Michael Krupka was a consultant with Bain & Company. In addition to his firm and portfolio responsibilities, Michael Krupka also serves on the Boards of the Boys and Girls Club of Boston and MetroLacrosse. Michael Krupka has a BA in Chemistry from Dartmouth College.
Follow Michael Krupka:
About Bain Capital Ventures: Bain Capital Ventures invests in seed to growth-stage startups that uses tech to disrupt existing markets or create entirely new ones.
Scott Friend
Partner of Bain Capital Ventures
Scott joined Bain Capital Ventures in 2006 after selling the company he co-founded, ProfitLogic, to Oracle. ProfitLogic was the leader in the world of retail analytics and price optimization solutions. Through the experience of building ProfitLogic from its initial three founders to a 300 person global software and solutions business serving the retail industry, Scott had the opportunity to get to know many of the most influential executives in the retail and apparel brand world. Not surprisingly, Scott’s areas of investment interest since joining BCV have revolved around the retail ecosystem, both online and offline as well as the convergence of the two, and he finds himself splitting time between New York City and Boston. Prior to Bain Capital Ventures, Scott was Chairman of the Executive Advisory Board and VP of Marketing & Science for Oracle Retail.Prior to its acquisition by Oracle in 2005, Scott was the President and co-founder of ProfitLogic which was a Bain Capital portfolio company.In 2005, Scott was named a winner of the Ernst & Young “Entrepreneur of the Year Award” in New England. Scott was also honored in 2004 as one of Chain Store Age’s “40 Under 40” most influential executives in the retail industry, and in 2006 received the Extended Retail Industry “Lifetime Achievement Award.” Prior to ProfitLogic, Scott held positions at Learning Sciences Corporation, an early pioneer in the e-learning space, The Parthenon Group, a management consulting firm, and IBM, where Scott’s customers were major retailers. Scott received an MBA, with distinction, from Harvard Business School and a BA, magna cum laude, in Electrical Engineering and Economics from Brown University. At Brown, Scott was captain of the Men’s Varsity Tennis Team and he continues, despite the futility of his efforts, to be a big supporter of Brown Athletics. Scott is a Cubs fan, so you know he roots for the underdog and never gives up hope! He also may be the only Venture Capitalist you’ll meet who knows who Herve Leger is, has visited Zac Posen’s design studio, has been to the runway shows during NY Fashion Week and has met Heidi Klum and Tim Gunn on Project Runway.
Follow Scott Friend:
About Bain Capital Ventures: Bain Capital Ventures invests in seed to growth-stage startups that uses tech to disrupt existing markets or create entirely new ones.
Paul Zurlo
Partner & COO of Bain Capital Ventures
Paul joined Bain Capital Ventures in 2007. Prior to Bain Capital Ventures, Paul was COO of Mercer Outsourcing, a $750M division of Mercer focused on benefit plan administration. Prior to that, he was the president of GoldK (acquired) and CFO of MCK Communications, a Summit Partners portfolio company that he helped take public. At Summit Partners, he made numerous other investments, including: SeaChange Int’l (NASDAQ: SEAC); DSET (NASDAQ: DSET), and Omtool (NASDAQ: OMTL). Paul started his career as a consultant with Bain & Company.
Follow Paul Zurlo:
About Bain Capital Ventures: Bain Capital Ventures invests in seed to growth-stage startups that uses tech to disrupt existing markets or create entirely new ones.
Axel Bichara
Partner and Founder of Bolt
Follow Axel Bichara:
About Bolt: Bolt is a pre-seed venture firm investing where the digital and physical world intersect.
Matt Thoms
Partner of Bolt
Follow Matt Thoms:
About Bolt: Bolt is a pre-seed venture firm investing where the digital and physical world intersect.
Nick Grossman
Partner of Union Square Ventures
Nick Grossman is a technologist and entrepreneur interested in the intersection of the web and urban, social and civic systems. For the past 10 years, he has developed software and media products, advocacy efforts, and internet-based businesses that help cities and the internet work better together. Grossman is currently the General Manager of Policy and Outreach at Union Square Ventures, where he works on public policy and regulatory issues facing peer networks on the web, and leads advocacy initiatives that support web-based innovation. He is also an advisor at Code for America and a visiting scholar at the Center for Civic Media at the MIT Media Lab. Previously, Grossman led an incubator for technology and media initiatives at OpenPlans by producing advocacy media properties focused on urban policy, building web applications to spark engagement in local civic issues, and building open source and open data businesses that serve the public sector. Nick Grossman has a BA in Urban Studies from Stanford University.
Follow Nick Grossman:
About Connected I/O, Union Square Ventures: Union Square Ventures is a venture capital firm focused on early-stage, growth-capital, late stage, and startup financing.
Benjamin Malka
Partner of Cota Capital
Follow Benjamin Malka:
About Cota Capital, Vestwell: Cota Capital is an SEC-registered multi-stage investment firm focused on private and public enterprise technology companies.
Jeff Immelt
Venture Partner of New Enterprise Associates
Immelt has held several global leadership positions since coming to GE in 1982, including roles in GE’s Plastics, Appliances, and Healthcare businesses. In 1989 he became an officer of GE and joined the GE Capital Board in 1997. Immelt has been named one of the World’s Best CEOs three times by Barron’s, and since he began serving as chief executive officer, GE has been named America’s Most Admired Company in a poll conducted by Fortunemagazine and one of The World’s Most Respected Companies in polls by Barron’s and the Financial Times. Immelt was the chair of President Obama’s Council on Jobs and Competitiveness. He is a member of The American Academy of Arts & Sciences. Immelt earned a B.A. degree in applied mathematics from Dartmouth College in 1978 and an M.B.A. from Harvard University in 1982. He and his wife have one daughter.
Follow Jeff Immelt:
About GE Appliances, GE Healthcare, GE Plastics, New Enterprise Associates, Stanford Graduate School of Business: New Enterprise Associates is a global venture capital firm investing in technology and healthcare.
Andrew Hedin
Partner of Bessemer Venture Partners
Andrew Hedin is a Board of Director at Kymera Therapeutics. He’s also the Vice President in Bessemer’s Cambridge office, where he focuses on investments in healthcare. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund. While there, he invested broadly across healthcare in early stage healthcare tech, healthcare services, biotech and medtech startups. Andrew has also worked with Health Essentials, a healthcare services company focused on providing post-acute and coordinated care to the frail elderly. Andrew began his career at Leerink Partners, a boutique healthcare-focused firm where he focused on growth strategies for pharmaceutical, biotech and medical device companies. Andrew holds an MBA with honors from The Wharton School, where he majored in Health Care Management and Finance, as well as a B.A. in Biological Basis of Behavior from the University of Pennsylvania, where he conducted research in both the neuroscience and psychology departments. Andrew also serves on the steering committee of the New England Venture Network, the largest group of young venture capitalists in the New England area.
Follow Andrew Hedin:
About Bessemer Venture Partners: Bessemer Venture Partners is a venture capital firm that funds consumer, enterprise, and healthcare startups.
Chris Gabrieli
Partner – Cambridge, Massachusetts Emeritus of Bessemer Venture Partners
Chris Gabrieli, a partner in Bessemer’s Cambridge, Mass. office, joined the firm in 1986 to launch its healthcare practice. In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology, healthcare services and education. Chris is closely involved in Bessemer’s investments in cancer-therapeutics firm AVEO Pharmaceuticals and biopharmaceutical firms Acceleron Pharma, Proteon, Oxagen and Transave. He serves on the board of digital textbook pioneer Flat World Knowledge. Among his past portfolio companies are biopharmaceutical company Affymax ( NASDAQ: AFFY); electronic health-record solutions company Allscripts (NASDAQ:MDRX); Isis Pharmaceuticals, a company that is the leading innovator in RNA-targeting pharmaceuticals; PerSeptive BioSystems, a maker of instruments for protein synthesis (acquired by Perkin-Elmer); Sirtris Pharmaceuticals, a developer of small-molecule drugs (NASDAQ: SIRT, acquired by GlaxoSmithKline); TravCorps, a pioneering healthcare-staffing company acquired by Cross Country Healthcare (CCRN); and VistaCare (NASDAQ:VSTA), a provider of hospice-care services. Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public and sell to the leading industry consolidator, McKesson (NYSE: MCK). Bessemer was an investor in GMIS. Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.
Follow Chris Gabrieli:
About Bessemer Venture Partners: Bessemer Venture Partners is a venture capital firm that funds consumer, enterprise, and healthcare startups.
Stephen Kraus
Partner of Bessemer Venture Partners
Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer since 2004 and focuses on the healthcare sector. Currently, he focuses his new deal activity on early and growth stage opportunities in healthcare IT and healthcare services. He currently sits on the boards of Liazon, Health Essentials, DocuTAP, Ovascience, Verastem, Allena Pharmaceuticals and Alcresta and is actively involved in BVP’s investments in Acceleron and Proteon. Steve has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), and Restore Medical (NASDAQ: REST), acquired by Medtronic. Prior to joining Bessemer, Steve was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts Steve graduated summa cum laude with a B.A. from Yale University and earned his MBA from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise. Steve was recently recognized by Forbes Magazine as one of the top life science investors if 2013. Steve regularly blogs with BVP’s Ambar Bhattacharyya at HCVC’s(two healthcare investors’ musings on work and life).
Follow Stephen Kraus:
About Bessemer Venture Partners: Bessemer Venture Partners is a venture capital firm that funds consumer, enterprise, and healthcare startups.
Kent Bennett
Partner of Bessemer Venture Partners
Follow Kent Bennett:
About Bessemer Venture Partners: Bessemer Venture Partners is a venture capital firm that funds consumer, enterprise, and healthcare startups.
TJ Rose
Partner of ABRY Partners
Follow TJ Rose:
About ABRY Partners: ABRY Partners is an equity firm focused on investments in media.
Royce Yudkoff
Managing Partner of ABRY Partners
Managing Partner at ABRY Partners.
Follow Royce Yudkoff:
About ABRY Partners: ABRY Partners is an equity firm focused on investments in media.
Nicholas Scola
Partner of ABRY Partners
Partner at ABRY Partners.
Follow Nicholas Scola:
About ABRY Partners: ABRY Partners is an equity firm focused on investments in media.
Brent Stone
Partner of ABRY Partners
Board member Brent Stone has been involved in a variety of media, information and business services investments and financings as a partner at ABRY Partners. His areas of focus have included insurance services, education, motion picture production and entertainment.
Follow Brent Stone:
About ABRY Partners: ABRY Partners is an equity firm focused on investments in media.
Dan MacKeigan
Founding Partner of Spring Lake Equity Partners
Dan is a founding partner of Spring Lake Equity Partners. Prior to founding Spring Lake, Dan served as a Partner in Tudor Investment Corporation’s private equity group, the predecessor to Spring Lake, since 2000. He has focused on investments in the wireless, mobile and internet sectors. Dan also currently serves on the board of RBM Technologies, Vantage, Vantrix, and ArcSoft. Prior investments where Dan served as a director or was actively involved include Wimba, N2 Broadband, Shoebuy, and Wavelink. Prior to Spring Lake Equity Partners, Dan spent three years as a Vice President and Senior Public Equity Research Analyst with Friedman, Billings, Ramsey, a Northern Virginia-based investment bank, focusing on public and private companies in the internet, media, and technology industries. As a public equity analyst, Dan conducted research on several emerging companies, including America Online, eBay, DoubleClick and Network Solutions. Dan was also a financial consultant for Zurich Investments. Dan holds a Bachelor of Science in Biology from Trinity College in Hartford.
Follow Dan MacKeigan:
About Spring Lake Equity Partners: Spring Lake Equity Partners is a Boston-based private equity firm. We invest equity capital primarily in later-stage, technology-oriented
Matthew Christensen
Founder, Managing Partner of Rose Park Advisors
Matthew Christensen is the CEO, Portfolio Manager, and co-founder (together with Clayton Christensen of Harvard Business School) of Rose Park Advisors, a Boston-based investment firm focused on investing in innovative companies. Matt is an expert in identifying and applying disruptive innovation frameworks and assessing whether management can capitalize on or defend against a disruptive strategy. Matt was formerly a Senior Associate at Innosight, leading engagements in the biotechnology, enterprise software, grocery, and financial services industries, among others. Mr. Christensen was also head of Innosight’s small business and workshops initiatives. Before Innosight, Mr. Christensen worked at the Boston Consulting Group, working on projects in various industries, including specialty chemicals, telecom, technology and industrial goods. Prior to receiving an MBA from Harvard Business School, Mr. Christensen graduated from Duke University with a BSc in economics and a BSE in civil engineering with an emphasis in structural engineering. While at Duke, he won a national championship in 2001, playing basketball for Coach Mike Krzyzewski. In 2002, he won the Coaches’ Award, given to the player best embodying the spirit of Duke Basketball, as well as the Dr. Deryl Hart Award (Top Scholar-Athlete). Christensen served as a missionary for The Church of Jesus Christ of Latter-day Saints in Frankfurt, Germany.
Follow Matthew Christensen:
About Rose Park Advisors: Rose Park Advisors is an investment firm focused on identifying investment opportunities by applying the framework of disruptive innovation.
Aaron Fleishman
Partner of Tola Capital
Mr. Fleishman is a Partner at Tola Capital where he invests in early stage B2B software companies. Prior to venture, Mr. Fleishman was a strategist and entrepreneur, with experience as a Strategy Manager at Microsoft and as an eCommerce startup CEO and Founder. Having been on both sides of the investment table, Mr. Fleishman leverages this dual perspective along with his financial, strategic, and operational expertise to identify compelling technology companies and investments. Prior to starting his own company, Mr. Fleishman worked as a Corporate Strategy and M&A Manager at Microsoft. His responsibilities included strategic planning, product strategy, market analysis, deal evaluation, due diligence, and post-deal integration. Mr. Fleishman evaluated acquisition targets ranging from $2M – $50B valuations, including product strategy and synergy analysis that resulted in the eventual $26B acquisition of LinkedIn. He also worked with executives at Microsoft to devise the company’s strategy in enterprise SaaS, cloud, and search. As the CEO and Founder of his own eCommerce startup, Mr. Fleishman conceived of a new business model for the $7B high-end apparel market and built a revenue-generating business in nine months. He built the user experience and back-end systems, managed marketing efforts, forged partnerships with multi-million dollar designer labels, and directed the long-term strategy and vision of the company. Mr. Fleishman worked at a hedge fund in New York earlier in his career and he is a graduate of The Wharton School of the University of Pennsylvania with a BSc in Finance and Entrepreneurship and a BA in International Studies.
Follow Aaron Fleishman:
About Tola Capital: Tola Capital is a venture capital firm that invests globally in enterprise software companies across multiple stages.
Amir Nashat
Managing Partner of Polaris Partners
Amir Nashat is a Managing Partner in Polaris’ Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare. Amir currently represents Polaris as a Member of the Board of Directors at AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences, and Syros Pharmaceuticals. Additionally, Amir has served as a Member of the Board of Directors at Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene) and Sun Catalytix (Lockheed Martin). At Living Proof and Sun Catalytix, Amir served as the company’s initial Chief Executive Officer. Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. Amir previously served on the Board of the New England Venture Capital Association. Amir has been named to the Forbes Midas List of “Top 100 Venture Capitalists.” Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. degree and B.S. degree in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Follow Amir Nashat:
About Polaris Partners, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
David Barrett
Managing Partner of Polaris Partners
20 yr operating exec & entrepreneur. Mentor, coach & partner to innovators, entrepreneurs & technology start-ups. 14 yr early & growth-stage investor focusing on SaaS, data/analytics, cloud infrastructure and healthcare technologies.
Follow David Barrett:
About Polaris Partners, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Terrance McGuire
Founding Partner of Polaris Partners
Mcguire has served as a member of Acceleron’s board of directors since 2005.McGuire co-founded Polaris Partners in 1996 and is currently one of their general partners.Prior to starting Polaris Partners,.McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical and information technology companies.He currently serves on the board of directors of Adimab/Arsanis, Aero Designs/Wiki Cells, Arsenal Medical/480 Biomedical, Iora Health, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, NextCode, Pulmatrix, SustainX, and Trevena. He has served on the board of directors of numerous other companies, including Remon Medical Technologies, GlycoFi, Akamai Technologies, Aspect Medical Systems, Cubist Pharmaceuticals, Transform Pharma, and deCODE genetics.McGuire is the former chairman of the National Venture Capital Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School. McGuire received a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.
Follow Terrance McGuire:
About Advanced Inhalation Research, Inspire Pharmaceuticals, MicroCHIPS, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Pat Kinsel
Partner of Polaris Partners
Pat Kinsel is a Venture Partner at Polaris Partners. He joined the firm in August 2013. Pat specializes in designing and building innovative technologies and consumer products. He has built products in the mobile, search, social, local, productivity, and collaboration spaces. Pat joined Polaris from Spindle, a company he co-founded and led as CEO from December 2010 until it was acquired by Twitter in June 2013. Spindle developed patent pending search technology to surface the most timely and interesting updates from services like Twitter and Facebook. Spindle’s technology advanced search by understanding the implicit context made available by mobile devices to compose a far richer query than a keyword alone ever could. Prior to Spindle, Pat spent several years at Microsoft leading teams within Microsoft FUSE Labs and Microsoft Startup Labs. Pat was responsible for incubating new concepts and bringing them to market. In this role, he led development of Docs.com. Launched by Mark Zuckerberg at F8 in 2010, Docs.com was a collaboration between Microsoft and Facebook to bring Microsoft Office Online to the Facebook audience. Before Docs.com, Pat built several social discovery applications and helped launch Bing’s social search efforts, ultimately bringing Bing Social Search to market in October 2009. At Microsoft, Pat was a co-inventor of several pending patents in the areas of social search and collaboration.
Follow Pat Kinsel:
About Harvard Innovation Labs, Notarize, Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Darren Carroll
Partner of Polaris Partners
Mr. Darren Carroll leads the New Ventures Division of Eli Lilly and Company which includes both Lilly Ventures and Lilly Asian Ventures where he is the Senior Managing Director. Prior to assuming his current role, Mr. Carroll was the founding chief executive officer of InnoCentive, Inc., the first e-business venture created by Lilly. Among other positions Mr. Carroll has held at Lilly, he was the U.S. attorney for Prozac®.
Follow Darren Carroll:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Dan Lombard
Partner of Polaris Partners
Dan joined Polaris as a Principal in 2015. He focuses primarily on growth equity investments and buyout opportunities in software and technology-enabled services. Prior to joining Polaris, Dan was a Vice President with H.I.G. Growth Partners, a private equity firm focused on recapitalizations of growth-oriented, lower middle market businesses. While at H.I.G., Dan was responsible for sourcing, executing and monitoring investments in software, internet, and business services. He also served on the boards of several companies. Previously, Dan served as an associate at Symmetric Capital, where he sourced and executed investments in software, healthcare and business services. He also was an investment banking analyst at Bank of America in San Francisco, where he worked with growth-oriented technology and healthcare companies on private capital raises and recapitalizations. Dan received his MBA from the Tuck School of Business at Dartmouth, where he was recognized as an Edward Tuck Scholar, and a BA from Yale University.
Follow Dan Lombard:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Richard D’Amore
General Partner of North Bridge Venture Partners & Growth Equity
Rich D’Amore has almost three decades of experience in the venture business. Rich D’Amore has been with North Bridge since the company’s inception in 1994. Before co-founding North Bridge, he spent fourteen years at Hambro International Equity Partners, establishing the firm’s Boston office. His investments have been split between early stage projects and special situations. Before joining Hambro in 1982, he worked as a consultant at Bain and Company and was a Certified Public Accountant with Arthur Young and Company. Rich received a BS from Northeastern, summa cum laude, in 1975. He also has an MBA from Harvard University Graduate School of Business Administration where he was a Baker Scholar. A dedicated supporter of higher education, he is on the Board of Trustees at Northeastern University, where he promotes innovation and research that can drive economic growth.
Follow Richard D’Amore:
About North Bridge Venture Partners & Growth Equity: North Bridge provides seed-to-growth stage funding for businesses in several sectors such as software, communications and infrastructure.
Ed Anderson
Founder & Managing Partner of North Bridge Venture Partners & Growth Equity
For the past 25 years, Ed Anderson has provided financing and advised entrepreneurs who are focused on building game-changing companies. Ed’s involvement almost always starts with a modest seed investment. Over the past three decades, Ed has had the good fortune to be involved as a seed or first round investor and director in some of the communications industry’s most successful start-ups including: Arris Networks (Cascade), Arrowpoint Communications (public), Broadband Access Systems (ADC Telecom), Camiant Networks (Tekelec), Cascade Communications (public), NetCore Systems (Tellabs), New Oak Communications (Bay Networks), Redstone Communications (Siemens), Sonus Networks (public), Spring Tide Networks (Lucent), Starent Networks (public), Sycamore Networks (public), SQA (public), Wellfleet Communications (public) and Winphoria Networks (Motorola). Ed is a graduate of the University of Denver and Columbia University Graduate School of Business. He has numerous philanthropic interests outside of North Bridge.
Follow Ed Anderson:
About North Bridge Venture Partners & Growth Equity: North Bridge provides seed-to-growth stage funding for businesses in several sectors such as software, communications and infrastructure.
Jeff McCarthy
General Partner of North Bridge Venture Partners & Growth Equity
Jeff McCarthy, General Partner, has a successful entrepreneurial track record in communications. As an investor he focuses mainly on materials. When Jeff joined North Bridge Venture Partners in 1998, he was well known to the company’s founding partners through his leadership roles at two early, successful companies within the North Bridge portfolio Cadia Networks and New Oak Communications and at Wellfleet Communications, an investment of the North Bridge founder. He was CEO of New Oak Communications, a leading provider of VPN switches, when the company was acquired by Bay Networks (a Nortel line of business). Subsequently, North Bridge acquired Jeff.
Follow Jeff McCarthy:
About G20 Ventures, North Bridge Venture Partners & Growth Equity, North Bridge Venture Partners & Growth Equity: North Bridge provides seed-to-growth stage funding for businesses in several sectors such as software, communications and infrastructure.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Douglas Cole
Managing Partner of Flagship Pioneering
Follow Douglas Cole:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Harry Wilcox
General Partner of Flagship Pioneering
Follow Harry Wilcox:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Stephen Berenson
Managing Partner of Flagship Pioneering
Follow Stephen Berenson:
About Flagship Pioneering, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Stacie Rader
Partner, Chief People Officer of Flagship Pioneering
Prior to joining BG Medicine, Ms. Rader was Vice President at Flagship Ventures and Vice President, Human Resources, of NewcoGen since 1999. During her tenure with Flagship, she has consulted with numerous portfolio entities on HR operational issues. Ms. Rader has particular expertise in team building, staffing, and organizational development as well as compensation and benefits design and implementation. Prior to Flagship Ventures, she was Corporate Director of Worldwide Employment and Staffing for Applera Corporation (now Applied Biosystems) following the merger of Perkin Elmer and PerSeptive Biosystems in 1998. Ms. Rader was responsible for all human resources functions at PerSeptive from 1992 to 1998. During this period, she oversaw the hiring of 600 global employees and the implementation of core HR processes and programs as well as equity and compensation structures to accommodate the company’s rapid growth. She was also a key member of corporate due diligence teams for a number of PerSeptive acquisitions and was instrumental in the integration and assimilation process for the PE-PerSeptive merger and held an interim Vice President, Human Resources, role at Celera Genomics. Ms. Rader holds a B.S. from Babson College.
Follow Stacie Rader:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Chip Hazard
General Partner of Flybridge
Full-time VC who thinks infrastructure software and AI is hip, part-time family Uber driver, photographer, and dogcatcher. Co-Founder and Investment Partner at XFactor Ventures.
Follow Chip Hazard:
About Datalogue, Einblick, Flybridge, Scitara, StackHawk, XFactor Ventures: Flybridge is a seed-stage venture capital firm investing with entrepreneurs to leverage the power of the community.
Jeff Bussgang
General Partner and Co-Founder of Flybridge
Jeff Bussgang is the General Partner and Co-Founder of Flybridge Capital Partners. He has a master’s degree in Business and Entrepreneurship at Harvard Business School.
Follow Jeff Bussgang:
About BloXroute Labs, Bowery Farming, Cartera Commerce, FalconX, Flybridge, Global EIR, Hack.Diversity, Harvard Business School, Hedron, Infracommerce, Plastiq, The Graduate Syndicate, Upromise: Flybridge is a seed-stage venture capital firm investing with entrepreneurs to leverage the power of the community.
Anna Palmer
General Partner of Flybridge
Anna is an entrepreneur with over four years in the start-up space. She holds a B.A. from Eureka College in Communications, Political Science, and History, and a J.D. from Harvard Law School. She has founded two non-profit organizations, served on three non-profit boards, and currently is an active volunteer for BUILD, an entrepreneurship program for high school students.
Follow Anna Palmer:
About Dough, Fashion Project, Flybridge, Wondermile, XFactor Ventures: Flybridge is a seed-stage venture capital firm investing with entrepreneurs to leverage the power of the community.
Craig Driscoll
General Partner of Highland Capital Partners
Craig is a General Partner at Highland Capital Partners, which he joined in 2006. Craig serves on the boards of Xometry, WhyHotel and Remote Year. He’s actively involved with Catalant and SessionM. He is a former director of Trilogy Education Services (acquired by 2U in 2019) and INXPO (acquired by West Corporation in 2018). He has also been involved in Bullhorn (acquired by Vista Equity Partners in 2012) and Quattro Wireless (acquired by Apple in 2010). Previously, Craig worked at Korn/Ferry, JacobsRimell (acquired by Amdocs), Fidelity Ventures, The Yankee Group, and Beacon Power Corporation (IPO in 2000). He holds a B.E. from Vanderbilt University.
Follow Craig Driscoll:
About Catalant, Highland Capital Partners: Highland Capital Partners is a venture capital firm that offers seed, early, and growth-stage funding solutions.
Habib Haddad
Managing Partner of The E14 Fund
Habib is a tech entrepreneur and angel investor, recently turned VC. He is currently the CEO of Wamda.com and the managing partner of Wamda Capital. He founded Yamli.com the Arabic search and transliteration startup that licensed its technology to Yahoo. He also started a number of non-profits including YallaStartup, INLET and ReliefLebanon. In 2009, the World Economic Forum recognized Habib as a Young Global Leader and the ArabianBusiness named him one of the top 30 influential Arabs under 30 as well as of the most 500 powerful Arabs. He currently serves on the Global Agenda Council on innovation. He is an advisor to several US and Middle Eastern startups and non-profits. Habib is behind the original idea behind Yamli, and today drives Yamli’s vision of empowering the Arabic language and users on the web. His responsibilities span from product strategy and design to business development. The World Economic Forum recently recognized Habib as a Young Global Leader for 2009. Prior to Yamli, he worked as a senior engineer at ATI (later acquired by AMD); and before that he was part of the early engineering team at Mok3 (now Everyscape), a startup out of the MIT CSAIL lab. Habib co-founded INLET (International Network of Lebanese Entrepreneurs and Technologists), an organization geared towards promoting entrepreneurship and leadership for the Arab world in general and Lebanon in particular. He also founded Relief Lebanon, a grass roots effort aimed at supporting the relief operations in Lebanon during the July 2006 war. Relief Lebanon was featured by the “101 Stories to Tell” initiative by the UNDP in February 2009. Habib often speaks about early stage development and entrepreneurship, and has spoken at venues such as the Harvard Business School, Boston College and the American University of Beirut. He currently sits on the advisory board of Meedan, a non-profit startup that aims to enable cross-cultural dialogs online. Habib holds a Bachelor of Computer and Communication Engineering from the American University in Beirut and a Masters in Electrical Engineering from the University of Southern California.
Follow Habib Haddad:
About Affectiva, Formlabs, MIT Media Lab, Ori, The E14 Fund, The World Economic Forum, Tulip Interfaces, Volta Labs: E14 Fund is an early stage venture fund focused on startups founded by the MIT community.
Rick Burnes
General Partner & Founder of CRV
Rick Burnes is the General Partner & Founder of Charles River Ventures.
Follow Rick Burnes:
About CRV: CRV is a venture capital firm that invests in early-stage investments in technology companies.
Murat Bicer
General Partner of CRV
Murat Bicer is the General Partner of CRV.
Follow Murat Bicer:
About CRV: CRV is a venture capital firm that invests in early-stage investments in technology companies.
Izhar Armony
General Partner of CRV
Izhar Armony is a Venture Capitalist at CRV. Since joining CRV in 1997, Izhar has built an impressive portfolio of startups and successful exits.Prior to joining CRV, Izhar was vice president of marketing at Onyx Interactive, a computer-based training company in Israel.Izhar holds an MBA from the Wharton School at the University of Pennsylvania, an M.A. in International Studies from the University of Pennsylvania, and studied Cognitive Psychology at Tel Aviv University. Izhar’s past portfolio investments include Aveksa (acquired by EMC in 2013), Vlingo (acquired by Nuance in 2012), Performable (acquired by Hubspot in 2011), iSkoot (acquired by Qualcomm in 2010), Conduit Labs (acquired by Zynga in 2010), Yantra (acquired by Sterling Commerce in 2005), iPhrase Technologies (acquired by IBM Corporation in 2005), ThinQ (acquired by Saba Software in 2005), Guardent (acquired by VeriSign in 2003), Oberon Software (acquired by OnDisplay in 2000), and iBasis (IPO in 1999).For fun, Izhar races off-road rally cars in long distance races in the Sahara and Atacama deserts.
Follow Izhar Armony:
About CRV: CRV is a venture capital firm that invests in early-stage investments in technology companies.
William Johnson
Operating Partner of Advent International
William Johnson is a Member of the Board of Directors at UPS since 2009. William is a Member of the Executive Committee and serves as the Lead Independent Director and Chairperson of the Nominating and Corporate Governance Committee. William is the former Chairman of the Board of Directors, President and Chief Executive Officer at the H. J. Heinz Company, offering high quality and healthy products worldwide. With more than $10 billion in annual sales, Heinz’s 50 companies have leading brands in more than 200 countries. The Heinz brand enjoys international renown and accounts for more than $3 billion in annual sales. Other well-known U.S. brands include Ore-Ida, Boston Market Homestyle Meals, T.G.I. Fridays, Classico and Bagel Bites. Among Heinz’s best-known overseas brands in addition to Heinz are, Plasmon, ABC, Wattie’s, Pudliszki, Complan, and Long Fong. William joined Heinz in 1982 as General Manager – New Businesses for Heinz USA. In 1984, William was promoted to Vice President – Marketing for Ketchup, Foodservice and Sauces. William was named President and Chief Executive Officer at Heinz Pet Products in 1988, and assumed leadership of Star-Kist Foods, Inc., in May 1992, when the pet food business and Star-Kist were re-united. These businesses were spun off and merged with Del Monte Foods in December 2002. In 1993, William was named Senior Vice President of Heinz and joined the company’s Board of Directors. William’s responsibilities included Heinz operations in the Asia/Pacific area, including Australia, New Zealand, China, Thailand and South Korea, in addition to the canned tuna and pet food businesses of Star-Kist Foods, Inc. William became President and Chief Operating Officer of Heinz in June 1996 and assumed the position of President and Chief Executive Officer on April 30, 1998. William was named Chairman of the Board of Directors, President and Chief Executive Officer on September 12, 2000. Prior to joining Heinz, William was employed by Drackett, Ralston Purina and Anderson-Clayton. William earned his Undergraduate degree from UCLA and his MBA from the University of Texas. An active supporter of community organizations, William has served as a Member of the National Athena Awards committee, chaired the 2001 annual campaign for the United Way of Western Pennsylvania, and chaired numerous local events including the 2004 Pittsburgh Cultural Trust gala event. In 2006, William received the inaugural Global Visionary Award from Helen Keller International for Heinz’s micronutrient program for combating childhood anemia. William also received the Marco Polo Award, the highest honor bestowed by the Chinese government on foreign business leaders, for Heinz’s support of the development of the Chinese food industry. William also serves on the Board of Directors of Emerson Electric Company, PepsiCo, Inc., the Grocery Manufacturers of America and is an active member of the University of Texas McCombs School of Business advisory council. In 2007, William was inducted into the Hall of Fame at the McCombs School of Business at the University of Texas.
Follow William Johnson:
About Advent International: Advent International is a global private equity firm that invests in the business and financial services.
Bob Chicoski
Founder & General Partner of Tech Pioneers Fund
Bob Chicoski is the founder and Managing Partner of Tech Pioneers Fund, a venture capital fund with offices in San Francisco, Boston and New York. Tech Pioneers Fund makes early and growth stage investments in pioneering companies in emerging and established info tech sectors. TPF is built around a “value network” of successful business leaders, including members of the World Economic Forum’s Technology Pioneers community. Tech Pioneers Fund works alongside top tier investors and provides targeted assistance to portfolio companies by leveraging the unique Tech Pioneers Fund network. This network serves to enhance returns and provide other derivative benefits to members. Tech Pioneers Fund portfolio companies include Compass, Orbital Insight, and Digisure. Prior to founding Tech Pioneers Fund, Bob was a General Partner at Saturn Partners, a Boston based venture capital fund, where he led investments in such companies as Alignable and Omaze. Previously, Bob worked for a family office; industry2industry; Deloitte Consulting; and the Federal Reserve Bank. He has also been an advisor to Pfizer and the Massachusetts Institute of Technology. Bob received an MBA from Harvard University and a BA in Economics from Georgetown University.
Follow Bob Chicoski:
About Tech Pioneers Fund: Tech Pioneers Fund is an independent and membership-driven venture capital fund investing in innovative technology companies.
Michael Ehlers
Chief Scientific Officer and Venture Partner of Apple Tree Partners
Follow Michael Ehlers:
About Apple Tree Partners, Aulos Bioscience, Intergalactic Therapeutics: Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Alex Benik
Partner of Battery Ventures
Alex joined Battery in 2001 and currently works out of Battery’s Waltham office. From 2001 through 2006, he was based in Menlo Park. Alex focuses on investments in infrastructure technologies for Enterprise, Data Centers, and wired/wireless service providers. He has also been actively involved in building Battery’s semiconductor portfolio. Alex is also the focal point for Battery’s relationships with technologists and end-users at Fortune 1000 enterprises and large web scale operators. He is particularly interested in the challenges of building web scale data center networks and distributed computing systems. During his tenure at Battery, Alex has been involved with several of the firm’s investments including Achronix, Anobit Technologies (acquired by Apple), Aurora Networks, Cumulus Networks, Diablo Technologies, MaxLinear (NYSE: MXL), Nutanix, Optichron, Tracelytics (acquired by AppNeta), Veraz Networks (NASDAQ: VRAZ), VSS Monitoring (acquired by Danaher), and ZeroG Wireless (acquired by Microchip). Prior to joining the firm, Alex was an Analyst at The Yankee Group, where he performed market research and consulting focused on local, wide area, and transport networks. While in this position, he executed strategic marketing and competitive analysis for clients including major telecommunications equipment and service providers. Alex earned a BA in Government from Wesleyan University. Alex co-authors www.thewholestack.com, a blog focused on infrastructure IT, and was named a top cloud investor by GigaOm in 2012.
Follow Alex Benik:
About Battery Ventures: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Morad Elhafed
General Partner of Battery Ventures
Morad joined Battery in 2008. He focuses primarily on growth and buyout investments in the Software and Internet sectors. Based in Battery’s Boston office, Morad is active in the firm’s investment activities in North America and Europe. He is involved with Battery’s investments in IHS, Jeeves Information Systems, SingleHop and Vero Software and was involved with Neolane prior to its acquisition by Adobe. Before Battery, Morad worked in the technology investment banking practice at RBC Capital Markets, where he focused on M&A, equity and debt financings. Morad graduated with a BBA from the Ross School of Business at the University of Michigan.
Follow Morad Elhafed:
About Battery Ventures: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Jesse Feldman
General Partner of Battery Ventures
Jesse Feldman is a General Partner at Battery Ventures.
Follow Jesse Feldman:
About Battery Ventures: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Michael Brown
General Partner of Battery Ventures
Since joining Battery Ventures in 1998, Michael has made, or managed, multiple investments in the areas of financial services, enterprise software and technology-enabled business services. Michael currently serves on the board of ExactTarget, Fingerhut Direct Marketing, Panjiva, and TradeKing. In addition, he has been actively involved with Battery’s investments in ChemConnect (acquired by InterContinental Exchange), The London International Financial Futures and Options Exchange (LIFFE) (acquired by Euronext), MRU Holdings, and OutlookSoft Corporation (acquired by SAP). From 1996 to 1998, Michael was a member of the High Technology Group at Goldman, Sachs & Co., where he worked on numerous debt and equity financings and merger and acquisition assignments. Previously, he was a Financial Analyst within Goldman’s Financial Institutions Group between 1994 and 1996, where he focused on merger and acquisition assignments within asset management, insurance, specialty finance and retail/mortgage banking. Michael graduated magna cum laude from Georgetown University with a dual BS in Finance and International Business.
Follow Michael Brown:
About Battery Ventures, Next Insurance, Placement Spot: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Zack Smotherman
Partner of Battery Ventures
Zack joined Battery in 2013 as a vice president and focuses on later-stage investments in industrial technologies. He is currently involved with Battery’s investments in James Heal and Noise & Vibration Technologies, a platform company created with Data Physics, Lansmont Corp. and Team Corp. Prior to Battery, Zack was an associate at WestView Capital Partners, where he evaluated and executed middle-market buyout and recapitalization transactions across the tech-enabled services and software sectors. Zack began his career in the investment banking group at Avondale Partners. Zack graduated magna cum laude from Tufts University with a BS in economics. He also holds an MBA from the MIT Sloan School of Management.
Follow Zack Smotherman:
About Battery Ventures: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Russell Fleischer
General Partner of Battery Ventures
Russell Fleischer, a three-time, software-industry CEO, joined Battery as a partner in 2014 and was promoted to general partner in 2015. He has also served as a longtime executive in residence at the firm. At Battery, Russell focuses on new investment opportunities in the enterprise-software sector. He is currently involved with Battery Ventures portfolio company Enviance and its add-on company Remedy Interactive. He also participated in the spin out and creation of Qognify, a company that Battery acquired from NICE Systems’ Physical Security Business Unit. His focus is later-stage deals, including buyouts, rollups and take-privates. He is also focused on developing new talent, both at Battery portfolio companies and inside the firm. Prior to joining Battery as a partner, Russell was the CEO of HighJump, a supply-chain management software company, and a member of the company’s board of directors. Under Russell’s four-plus years of leadership the business grew to $110M in revenues and a worldwide workforce of over 500 people from $50M in revenue. In July of 2014 the company was acquired by Accel|KKR and merged with Accellos. Before that Russell served as CEO of Healthvision Software, a healthcare information-technology provider. Healthvision was acquired by Lawson Software in 2010. Russell and his team grew Healthvision from a company with $25 million in revenue into a global business employing more than 300 people and generating approximately $70 million in revenue and $20 million in EBITDA. Prior to Healthvision, Russell served as CEO of TriSyn Group, a core banking applications-software provider focused on serving the top 100 banks in the U.S. There, he was responsible for launching the company as a standalone entity after its acquisition from Computer Associates. In addition, he has over time served as a board director for many public and private companies, including Adams Golf, HomeCareHomeBase, Vero Software, Data Innovations and RogueWave. Russell has been both a public- and private-company CFO, primarily in the software sector, for InConcert, InterWorld and Adams Golf. He also worked with CheckFree, D&B Software, Sales Technologies and Xerox. Russell earned a BA in economics from Johns Hopkins University and an MBA from Vanderbilt. He is a board member and trustee for Cooks Children’s Hospital in Fort Worth and a board member for the Michael E. Nozik Foundation in Rochester, NY, which raises funds to send deserving children to Camp Seneca Lake in the Finger Lakes of western New York.
Follow Russell Fleischer:
About Battery Ventures, Healthvision Solutions: Battery Ventures finances technology sector companies with venture capital, private equity, and debt financing investments.
Blake Bartlett
Partner of OpenView
Blake helps identify value and lead investments in product-led businesses driving market dislocation. Prior to joining OpenView, he was a Vice President at Battery Ventures, where he focused on growth-stage software and Internet businesses. Blake joined Battery in 2009 and helped lead 10 investments, including Wayfair, Optimizely, Sprinklr, Catchpoint, Glassdoor, Tealium, Q2eBanking, Mass Relevance, and VSS Monitoring (acquired by Danaher). He began his career in the growth equity group at Kayne Anderson, a $25 billion private equity firm in Los Angeles.
Follow Blake Bartlett:
About OpenView, Postscript, Zipwhip: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Mackey Craven
Partner of OpenView
Mackey focuses on investments in the software and internet sectors, partnering with management teams to build enduring value Prior to joining OpenView, Mackey was an Associate at Bessemer Venture Partners focusing on investments in cloud computing, consumer internet, and data infrastructure. At Bessemer, Mackey was a Board Observer at Xtime, Twitch, and Apperian and was involved with the Bessemer’s investments in Infinio, Liazon, Zapier, and Intigua. He began his career in research and teaching positions at the Sloan School of Management and in the Departments of Physics and Biology at MIT where he co-founded BioVolt, a company focused on designing low-cost microbial fuel cells for use in the developing world. He has also served as an independent scientific consultant to Continuum Energy Technologies and analyzed PIPE and SPAC opportunities for Hudson Bay Capital Management. Mackey graduated Phi Beta Kappa from MIT with an S.M. in Technology and Policy, an S.B. in Biological Engineering, and an S.B. in Mathematics in four years
Follow Mackey Craven:
About Applitools, Axonius, Balena, Cogito, JumpCloud, Logz.io, OpenView, UserTesting: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
George Roberts
Venture Partner of OpenView
George Roberts is the Venture Partner at OpenView.
Follow George Roberts:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Ricky Pelletier
Partner of OpenView
At OpenView, Ricky focuses on identifying and analyzing various market and investment opportunities and works with other members of the investment team to structure and conduct diligence on new investments. Ricky is a Board Director at Intronis, SmashFly, and Open-E, and is active as a Board Observer at FieldLens, Spredfast, and FieldAware. Prior to joining OpenView, Ricky was an Associate at Symmetric Capital, a growth-focused private equity firm investing across industries. He previously interned at Landmark Partners, an investment firm centered on acquiring secondary interests in venture capital and private equity funds.
Follow Ricky Pelletier:
About OpenView, Optimize.health, Pipefy, project44, VTS: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Sanjiv Kalevar
Partner of OpenView
Sanjiv joined Battery in 2013 and focuses on Internet, SaaS/software and digital media investments. Prior to Battery, Sanjiv worked for Bessemer Venture Partners, a global venture capital firm with offices in the U.S., India, Brazil, and Israel. Sanjiv also worked with an early-stage angel investment group in Chicago and with 37signals, makers of the popular project management software Basecamp. Previously, Sanjiv was Business Development Manager with Constellation Software (TSX:CSU), where he helped grow his division 5X through a combination of organic and inorganic growth initiatives. Sanjiv graduated from Queen’s University in Ontario, Canada and holds an MBA from the University of Chicago Booth.
Follow Sanjiv Kalevar:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Elizabeth Cain
Partner of OpenView
Liz Cain is a Partner at OpenView where she leads the firm’s Expansion Platform and sits on the Investment Committee. The Expansion team focuses on helping portfolio companies acquire and retain the right customers and talent.
Follow Elizabeth Cain:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Dan Demmer
Partner of OpenView
Dan is an operator from the software industry and joined OpenView in 2013. Prior to joining OpenView, he spent more than 25 years as a leader in business management and corporate finance, having served as a President, COO, CFO, and Board Member in high-growth software enterprises. His areas of expertise include business expansion strategy and execution, executive organization design and development, merger and acquisition strategy and execution, and IPO preparation. As President and Chief Financial Officer of Endeca Technologies, Dan led the venture-backed, information analytics software company on a path of rapid revenue growth and profitability. Endeca was acquired by Oracle Corporation in late 2011. Previous to Endeca, he served as Chief Financial Officer of IONA Technologies, a high-growth, public software company specializing in application integration solutions. Prior to that, Dan held a variety of leadership positions at Digital Equipment Corporation. Dan is a member of the board of directors of DataXu, Sonian, and iLevel Solutions.
Follow Dan Demmer:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
John McCullough
Partner of OpenView
John works closely with OpenView’s portfolio companies to help strengthen business and corporate development activities with the aim of driving growth and strategic exits. He focuses on identifying potential strategic acquirers, facilitating engagements that result in alliance partnerships, driving M&A and capital raise outcomes, and building and maintaining relationships with the global investment banking community. Prior to joining OpenView, John was Director of Corporate Development at Rocket Software, a global enterprise software company where he drove inorganic growth initiatives and business development activities; while there he successfully executed 10 acquisitions, including public company carve-outs, stock purchases, and cross-border transactions. Before Rocket, John focused on M&A as an investment banker at Barclays Capital, and he has also held various roles within the asset management industry. John graduated with a bachelor’s degree, cum laude, from Providence College, and earned his MBA from the Tuck School of Business at Dartmouth College. He also holds the Chartered Financial Analyst designation.
Follow John McCullough:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Devon McDonald
Partner of OpenView
Devon is responsible for working directly with key stakeholders within OpenView’s portfolio to provide strategic guidance in the areas of sales, marketing and influencer channel development, as well as operational efficiencies. Her team supports the portfolio in building repeatable and scalable sales and marketing processes that map specifically to a company’s target segments, buyer peDevon is a Partner at OpenView where she manages the firm’s Ecosystem and sits on OpenView’s investment committee. Over the course of her nine year tenure, she has led efforts in Marketing, Recruiting and Sales support for the firm’s portfolio companies. Today, she focuses on connecting our portfolio with OpenView’s network of executives, advisors and customers.rsonas, and buyers’ journeys. Her team also assists in creating impactful messaging and content, developing training/onboarding programs, and establishing sound management rhythms within sales and marketing organizations. Under Devon’s direction, the Sales and Marketing Support team has launched over a dozen lead qualification programs for OpenView’s portfolio companies. Her team has produced valuable eBooks such as Building Your Sales Funnel: How to Create an Outbound Prospecting Machine and the Sales Forecast: A Question of Method Not Magic. Prior to joining OpenView, Devon built and managed the sales and marketing recruitment team at Michael Page International in Boston. Previous to this, she focused on financial services recruiting and set an office record for the greatest single recruitment fee from a direct placement.
Follow Devon McDonald:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Peter Weed
Partner of OpenView
Peter Weed joined Lumia Capital in 2017 to further enhance the firm’s data-centric approach to identifying, investing in and scaling globally-dominant SaaS innovators. As part of his leadership role, Peter oversees Lumia’s “Global Success” platform, including its team and broader partner community, research and data initiatives and portfolio execution. By pairing LGS’s collective global insights, relationships and operational capabilities with his years of experience benchmarking and helping scale hundreds of global category-leading innovators, Peter helps ensure Lumia is a market-leading partner for the next wave of SaaS leaders as well as Lumia’s strategic investors and partners, globally. Prior to Lumia, Peter was a Partner at McKinsey & Company, where he was co-founder and global co-head of the ‘Growth Tech’ Practice. In this role he worked with dozens of best-in-class venture capital firms and hundreds of venture-backed innovators, helping companies achieve and maintain category-leading positions scaling from $10 million to $100 million, and beyond. This success was supported by deep insight creation, including codifying and benchmarking hundreds of SaaS innovators on 40+ critical growth and cost structure related metrics (e.g., sales acquisition speed/efficiency, marketing return, and churn) and providing insights across critical pain points such as commercial strategy, go-to-market efficiency, pricing, and customer success. Especially relevant to his work at Lumia, Peter’s practice approached these critical issues from a global lens and execution framework, enabled by dedicated full-time teams across the globe, including Silicon Valley, New York/Boston, London, Berlin, Israel, India, and Hong Kong/China — alongside McKinsey’s broader global footprint and access. Peter was also a leader in McKinsey’s TMT practice, where he drove proprietary knowledge leadership and authorship focused at the cutting edge of broader McKinsey clients’ businesses. In his earlier career at McKinsey, Peter worked extensively with global market-leading tech companies, including enterprise SW/SaaS and infrastructure players, consumer internet/SaaS/XaaS players, network infrastructure OEMs, consumer mobile/PC/device OEMs, micro-chip vendors, and telecoms/MSOs – a majority of the work was on step-out growth strategy in areas of his core knowledge focus (SaaS, mobility, and IoT) and the related key execution and operations of the product pipeline (e.g., design, pricing, COGS, and GTM). Prior to McKinsey, Peter was a Product Manager in Microsoft’s Enterprise Server Division, a software entrepreneur, and helped commercialize software technology out of Harvard and MIT as part of a dot-com era VC fund. Peter holds a BA in Economics from Harvard University (2000), and MBA with Highest Distinction (Valedictorian) from the Tuck School of Business at Dartmouth.
Follow Peter Weed:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Brian Carthas
Partner of OpenView
Brian is responsible for the identification of potential investment opportunities on behalf of OpenView Venture Partners. He particularly enjoys connecting with impassioned entrepreneurs and discussing the potential of their respective businesses. Prior to joining OpenView, Brian served as a Senior Consultant at Kingston Dwight Associates in Boston, where he recruited senior level executives in the finance and accounting arena. Brian graduated from Princeton University in 2006 with a BA in International Politics and Economics.
Follow Brian Carthas:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Casey Renner
Partner of OpenView
Follow Casey Renner:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Kyle Poyar
Partner of OpenView
Kyle helps OpenView’s portfolio companies accelerate top-line growth through segmentation, value proposition, packaging & pricing, customer insights, channel partner programs, new market entry and go-to-market strategy.
Follow Kyle Poyar:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Liz Cain
Venture Partner of OpenView
Liz Cain is a Venture Partner at OpenView.
Follow Liz Cain:
About OpenView: OpenView is an expansion stage venture firm that helps grow software companies into market leaders.
Harry Kubetz
Operating Partner of Greenhouse Capital Partners
Follow Harry Kubetz:
About Greenhouse Capital Partners: Greenhouse Capital invests growth capital in companies promoting health & sustainability within the areas of Food, Ag and the Environment
Carl Byers
Partner of F-Prime Capital
Carl Byers brings more than 15 years of experience in healthcare to his role as Executive Partner.Carl was on the founding team at athenahealth, Inc. (Nasdaq: ATHN), where he served as Chief Financial Officer from 1997 to 2010. At athenahealth, Carl was responsible for the company’s finance, legal and corporate technology teams and served as a key advisor to the CEO as part of the Senior Leadership Team. When a private company, he built the company’s financial systems and led seven rounds of equity and subordinated debt financing, raising more than $70 million to support the company’s development. Carl led athenahealth’s $96 million 2007 Initial Public Offering, which the Wall Street Journal named as the year’s most successful. In his tenure, he also held various operational roles at different times. Prior to the founding of athenahealth, Carl was a Senior Consultant in Booz, Allen & Hamilton’s New York office, where he worked in the financial services and health insurance industries. Carl teaches entrepreneurial finance at Harvard’s Kennedy School where he is an Adjunct Lecturer on Public Policy. He is a director at Lexington Montessori School, a co-trustee of the Bush Trust and an advisor to the Patricelli Center for Social Entrepreneurship at Wesleyan University (CT)
Follow Carl Byers:
About F-Prime Capital, Harvard Kennedy School of Government: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Jon Lim
Partner of F-Prime Capital
Jon Lim is a Partner who joined F-Prime Capital in 2011. Jon leads F-Prime’s investment efforts in Healthcare IT and Healthcare services, including F-Prime Capital’s investments in Liazon (acquired by Towers Watson), PatientPing, Kyruus, US HealthVest, Stride Health, TraceLink, VitalWare, WelbeHealth, Artemis Health, Protenus, Novaerus, and Lumere (formerly Procured Health). Most recently, Jon was a Principal at Polaris Partners, where he was part of the teams that led investments in several Software-as-a-Service companies (Phytel (acquired by IBM), Egnyte, Recurly, and KISSmetrics) as well as in Ocular Therapeutix (NASDAQ: OCUL) and SustainX. Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business. Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.
Follow Jon Lim:
About F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Ben Auspitz
Partner of F-Prime Capital
Ben is a Partner at F-Prime Capital and has worked in pharmaceuticals and life science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from the assay stage into phase II clinical studies and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics. He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals, and Compass Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ: DMTX), and Ultragenyx (NASDAQ: RARE)
Follow Ben Auspitz:
About Compass Therapeutics, Inc., F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Gaurav Tuli
Partner of F-Prime Capital
Gaurav is a Partner at F-Prime Capital, the global venture capital firm affiliated with Fidelity Investments. For over 50 years, F-Prime Capital has had the privilege of backing ground-breaking companies in technology and life sciences, including Atari, Nuance Software, Alibaba and Denali to name a few. Gaurav leads investments in enterprise technology and serves on the boards of Threat Stack, Riskrecon, Protenus, OTA Insight and previously Appsflyer and Neo Technology. Most recently, Gaurav was a Principal at F-Prime’s sister fund, Eight Roads Ventures, based in London, where he invested in European software and online services businesses. Previously, Gaurav was at EMC where he drove new growth initiatives and product portfolio management for EMC’s largest business unit, Symmetrix. Gaurav was a computer scientist by training and has worked as a software engineer at NASA, the U.S. Air Force and Motorola. Gaurav attended MIT for his bachelors and masters degrees in computer science, as well as his MBA.
Follow Gaurav Tuli:
About F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Thomas R. Beck
Executive Partner of F-Prime Capital
Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development. Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University. Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the board of Adagene, Ltd. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics.
Follow Thomas R. Beck:
About F-Prime Capital, Promentis Pharmaceuticals, Topaz Pharmaceuticals Inc: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Robert Weisskoff
Partner of F-Prime Capital
Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents. Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa. Robert serves on the Board of Directors of Caribou Biosciences, Plasmagen Biosciences, Tempest Therapeutics, Trivitron Healthcare, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Laurus Labs (NSE:LAURUSLABS), Surface Oncology, Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), and ViewRay (NASDAQ:VRAY).
Follow Robert Weisskoff:
About F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Sanjay Aggarwal
Venture Partner of F-Prime Capital
Sanjay Aggarwal is a Venture Partner focused on enterprise software and financial technology investments. Prior to joining F-Prime Capital, Sanjay was CEO of Unicel Technologies, an India-focused mobile CRM company. During his tenure with Unicel, he grew revenues by 6x, leading to a successful sale of the business to mGage India. Earlier in his career, Sanjay worked at Devonshire Investors (the private equity group of Fidelity Investments), McKinsey and Company in their US and India offices, and at Berkeley Process Control (acquired by Moog Inc), where he built advanced machine control systems. Sanjay holds a B.S. in Mechanical Engineering from MIT, an M.S. in Mechanical Engineering from UC Berkeley, and an M.B.A. from the MIT Sloan School of Management.
Follow Sanjay Aggarwal:
About Eight Roads Ventures, F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Ketan Patel
Partner of F-Prime Capital
Prior to joining Fidelity Biosciences, Dr. Patel was an engagement manager in the MEDACorp consulting division of Leerink Swann & Company. While at MEDACorp, he worked for a broad spectrum of clients ranging from biotech to leading pharmaceutical and device companies. Dr. Patel advised clients on brand strategy, clinical development plans, and business development activities. Prior to this, he was a physician at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training. Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.
Follow Ketan Patel:
About F-Prime Capital: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Jay Farber
Venture Partner of F-Prime Capital
Head of Growth at Juniper Square.
Follow Jay Farber:
About F-Prime Capital, Juniper Square: F-Prime Capital is a venture capital firm investing in healthcare and technology.
Jit Saxena
Limited Partner of G20 Ventures
Jit has served as a Member of the Board of Directors at Demandware, Inc. since July 2010. Jit founded Netezza Corporation, a leading data warehouse appliance provider, in September 2000 and served as Chief Executive Officer and a Member of the Board of Directors of Netezza from its inception until January 2009. Jit served as Chairman of Netezza’s Board of Directors from February 2009 until it was acquired by IBM in November 2010. Prior to founding Netezza, Jit served as Chairman and Chief Executive Officer of Applix, Inc., a provider of performance management applications, from 1983 until 2000. Jit currently serves on the board of directors of several private companies. Jit holds a B.S. in Electrical Engineering from IIT Mumbai, an M.S. in Electrical Engineering from Michigan State University and an M.B.A. from Boston University.
Follow Jit Saxena:
About G20 Ventures: G20 Ventures invests in enterprise tech startups in the early stages of their growth.
Michael Troiano
Partner of G20 Ventures
Mike is a venture capitalist who brings nearly 25 years of executive leadership and marketing experience to bear for entrepreneurs. He most recently served as the Chief Marketing Officer of Actifio, a global enterprise data-as-a-service provider he helped turn from an obscure virtualization technology into a venture capital “unicorn” valued at over $1.2 Billion. As CMO from 2012 to 2017, Mike helped grow revenue over 80% per year, creating the Copy Data Virtualization category while expanding the business into blue chip accounts across 37 countries. He spent his early career at top worldwide ad agencies including McCann-Erickson and FCB, and was named the founding CEO of Ogilvy & Mather Interactive in 1995. He later served as the president of NASDAQ-listed systems integrator Primix, and as General Manager of mobile content pioneer m-Qube from inception through one of the largest Boston-based venture capital exits of 2006. Mike is a graduate of Cornell and the Harvard Business School, a TechStars mentor, a Board Member of the New England Venture Capital Association, and a strategic advisor to Actifio. He is ranked in the top 1% of the most influential people on Twitter and among the most popular writers on venture capital and entrepreneurship on Medium, and hosts the popular Boston startup community podcast How Hard Can It Be?
Follow Michael Troiano:
About G20 Ventures: G20 Ventures invests in enterprise tech startups in the early stages of their growth.
Rick Grinnell
Founder, Managing Partner of Glasswing Ventures
Rick co-founded TD Capital Ventures in 2001 and Fairhaven Capital Partners in 2007. He has invested and served on the boards of companies including: Brabeion, Bridgeport Networks (acquired by Counterpath), Dataupia, Everypoint and EqualLogic (acquired by Dell). Rick held senior marketing positions at Adero, Inc and ClearOne Communications, and held senior engineering and marketing positions at PictureTel. He worked for General Electric and Fidelity Ventures. Rick earned BS and MS degrees in Electrical Engineering from MIT and an MBA from The Harvard Business School.
Follow Rick Grinnell:
About Glasswing Ventures: Glasswing Ventures is an early-stage VC firm investing in next gen AI and frontier technology startups enabling the intelligent enterprise.
Vlad Sejnoha
Venture Partner of Glasswing Ventures
As Nuance’s Chief Technology Officer, Vlad Sejnoha oversees Nuance’s research and focuses on core technology and product strategy, with an emphasis on emerging areas including natural language processing and mobile applications. Prior to joining Nuance, Vlad was the Chief Scientist at L&H, and earlier at Kurzweil AI, where he was responsible for creating technology for a number of commercially successful speech recognition products, including large vocabulary continuous speech dictation systems. Vlad has over 20 years’ experience in the field of speech recognition and holds thirteen U.S. patents. He earned a BS and Master’s degree in Electrical Engineering from McGill University.
Follow Vlad Sejnoha:
About Glasswing Ventures: Glasswing Ventures is an early-stage VC firm investing in next gen AI and frontier technology startups enabling the intelligent enterprise.
Kush Parmar
Managing Partner of 5AM Ventures
Kush Parmar is a Principal at 5AM Ventures, a leading life sciences venture capital firm, where he develops investment opportunities, negotiates financings and actively advises portfolio companies. Prior to joining 5AM, he trained at Harvard Medical School, where he was an NIH-sponsored MD/Ph.D. Physician Scientist Trainee in the joint Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. Kush Parmar’s Ph.D. work at Harvard unveiled a novel paradigm of how blood flow leads to “healthy” changes in arteries, published in The Journal of Clinical Investigation, Journal of Biological Chemistry and others. In addition, he attended courses at Harvard Business School in private equity and finance and consulted for a Boston area oncology startup. Kush Parmar holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Kush Parmar is a Board Observer for Achaogen, Atterocor, Cleave Biosciences, Envoy Therapeutics, Novira Therapeutics and Pulmatrix.
Follow Kush Parmar:
About 5AM Ventures: 5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Mason Freeman
Venture Partner of 5AM Ventures
Mason Freeman, M.D. joined 5AM Ventures as a Scientific Advisor in 2007 and became a Venture Partner in 2008. He serves as Chief of the Lipid Metabolism Unit and Director of Translational Medicine at Massachusetts General Hospital (MGH), Harvard Medical School. Dr. Freeman currently serves as clinical advisor to Relypsa and previously served as Board Director for Envoy (acquired by Takeda). Trained in internal medicine and endocrinology, Dr. Freeman has spent twenty years studying the trafficking of cholesterol into and out of macrophages. As a post-doctoral research fellow in the Biology Department at MIT he cloned the first macrophage scavenger receptor to be molecularly identified. In 1992 he became Chief of the MGH’s Lipid Metabolism Unit, which he continues to direct as well as the Translational Medicine programs at the MGH Center for Computational and Integrative Biology and the MGH Clinical Research Program. In these roles he oversees a basic science research laboratory devoted to studying lipid trafficking as well as a clinical investigative team developing a novel oral anti-diabetic drug.
Follow Mason Freeman:
About 5AM Ventures, Harvard Medical School, Massachusetts General Hospital: 5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
